Vibrating at up to 30,000 times per second, the sonographic device helps tissue to detach more easily without inflicting a large puncture wound to collect an adequate amount of tissue.

The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.

First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer. 

Leaders involved in the new facility’s development estimate it will increase global Ac-225 production capacity twentyfold. 

Matthew S. Davenport, MD, MBA, and Scott B. Reeder, MD, PhD, made their plea to patients and providers in an opinion piece published May 6 in JAMA.

Eden Radioisotopes believes the facility will have the capacity to produce up to 50% of the global demand for Mo-99 once completed.

Imaging findings could explain why treatments involving aspirin and other antiplatelet drugs are not effective in some stroke patients. 

As precision cardiology continues to evolve, the integration of advanced coronary computed tomography angiography (CCTA) and AI-driven analysis is fundamentally changing how we assess and manage coronary artery disease (CAD). Here is a closer look at how Heartflow Plaque Staging is leveraging Total Plaque Volume (TPV) to stratify patient risk.